Brief: MedinCell Targets Anti-Malaria Injectable First Clinical Trial In 2023

Medincell SA

14/06/2021 17:35

June 14 (Reuters) - MEDINCELL SA  MEDCL.PA :
    * MEDINCELL'S LONG-ACTING INJECTABLE TO FIGHT MALARIA READY
TO
ENTER REGULATORY DEVELOPMENT
    * MEDINCELL AND PROJECT CONSORTIUM MEMBERS, IRD, IRSS AND
CIRDES,
HAVE SUCCESSFULLY DESIGNED, TESTED, AND CONFIRMED WITH UNITAID
SELECTION OF LEAD FORMULATION
    * REGULATORY PRECLINICAL ACTIVITIES ARE STARTING WITH
OBJECTIVE OF
A FIRST CLINICAL TRIAL IN 2023

Source text for Eikon:  ID:nBwjG0Qra 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))